The patient received the Johnson & Johnson (Janssen) vaccine elsewhere and was later admitted to the UCHealth Emergency Department.
AURORA, Colo – A patient admitted to the University Hospital’s (UCHealth) emergency department with blood clots developed from the Johnson and Johnson (Janssen) vaccine was treated with an alternative blood thinner per day. Centers for Disease Control and Prevention (CDC) guidance according to the hospital.
> The video above is from a CDC conference where a US health panel calls for restarting J&J COVID-1
On April 13, the day the CDC placed a break on Johnson and the Johnson vaccine, a patient was brought to UCHealth suffering from vaccine-induced thrombotic thrombocytopenia (VITT), the hospital said.
The patient, a woman in her 40s, came to the emergency room 12 days after receiving the Johnson and Johnson vaccine, according to the hospital.
The CDC had warned that these blood clots, which could occur as a result of a rare complication of the Johnson and Johnson vaccine, should not be treated with the usual first-line drug, heparin, which could make the clots worse, UCHealth said in a release.
The CDC did not specify which alternative to use in these cases, UCHealth said. University of Colorado School of Medicine doctors worked quickly to recognize the condition and treat the patient with an alternative blood thinner, bivalirudin, the hospital said.
“Our experience shows us that these blood clot reactions are very rare and that they can be treated,” said R. Todd Clark, MD, MBA, lead author and assistant professor of emergency medicine at the University of Colorado School of Medicine. “People can feel safe being vaccinated with any of the approved vaccines, including the J&J vaccine. Getting vaccinated is a critical step in combating this pandemic so that we can return to our normal lives. ”
“The one-dose vaccination option will be convenient to give to patients in our emergency departments who may not have received the vaccine yet due to various barriers,” said Dr. Richard Zane, UCHealth Innovation Manager and Professor and Chair of Emergency Medicine at the University of Colorado School of Medicine. “Although the risk of developing blood clots is extremely rare, we know that this condition can be treated safely. In the very unlikely event that a patient develops VITT, they would be in good hands with a team of people who can treat it. ”
This was the first known case of a patient with VITT treated with a heparin alternative following the CDC guidelines according to the hospital.
RELATED: Out of 139,000 J&J shots, three reports of blood clots in Colorado
RELATED: Colorado recommends immediate restart of J&J vaccine, some providers choose to take it slow
SUGGESTED VIDEOS: Latest from 9NEWS